Dexa-Polyspectran

Drops

Active constituents: -2

1 ml contains 1.32 mg dexamethasone sodium phosphate (corresponds to 1 mg dexamethasone), 7500 IU polymyxin B sulfate, 5 mg neomycin sulfate and 0.02 mg gramicidin.

Indications: 4

Ophthalmology: Non-purulent infections of the external eye and the lacrimal apparatus, mixed infections caused by Dexa-Polyspectran sensitive bacteria, lesions or chemical burns of the cornea and conjunctiva, after removal of foreign bodies and after eye surgery, allergic or noninfectious irritations of the eye with susceptibility to infection. Oftology: Bacterial infections with marked secretion, concomitant allergic reactions, otitis externa and media, state after radical operations and tympanoplasty.

Contraindications:



Ophthalmology Glaucoma, corneal injuries and ulcers. Otology: In cases of suspected fracture of the base of the scull and of liquor fistula, Dexa-Polyspectran should not be used. On these conditions, gramicidin may induce meningitis and increase of cerebrospinal pressure. Vaccination reactions. In perforated ear drum, therapy should carefully be controlled by the physician. Treatment should not be continued for more than ten days to avoid impairment of the hearing due to neomycin. Hypersensitivity to a component of the medication.

In any case of viral, fungal and tuberculous infection Dexa-Polyspectran Drops may only be administered if an additional specific treatment is initiated.

Dexa-Polyspectran Drops should be used during pregnancy and lactation only if the potential benefit justifies the potential risk to the mother and the fetus/infant.

Side effects:



Ophthalmology: Prolonged treatment may lead to cataract formation, and in predisposed patients, elevation of intraocular pressure with possible development of glaucoma may occur. During therapy after eye surgery, it cannot be excluded that conjunctival irritation and superficial punctate keratitis may occur in rare cases. Regular postoperative slit lamp examinations by an ophthalmologist are recommended to check for superficial punctate keratitis. In case of a positive finding, therapy with Dexa-Polyspectran should be discontinued. Otology: In prolonged topical use: skin atrophy, telangiectases, striae, steroid acne. Prolonged therapy with high doses or of large areas may induce systemic steroid effects.

Dosage and administration:



Ophthalmology: Unless otherwise prescribed, instil 1 drop into the affected eye 3 to 5 times daily. Otology: Unless otherwise prescribed. instil 2 to 3 drops into the affected ear 3 to 5 times daily.

After fading of all symptoms the treatment should be continued for several days to prevent recurrence of the infection.

Usually the therapy should not be extended to more than 14 days. The duration as well as the result of treatment and the intraocular pressure (in case of application to the eye) should be controlled by the physician. The administration of Dexa-Polyspec-

tran Drops is shown below.

0292PP 35262-A

Dexa-Polyspectran Drops

Special warnings:

Contact lenses should not be worn during therapy with Dexa-Polyspectran Drops.

Likewise Dexa-Polyspectran Drops should not be used after the expiry date printed on the label. Dexa-Polyspectran Drops should be discarded one month after first opening.

Store at room temperature.

Medicines should be kept out of the reach of children.

For more information, please consult the doctor or pharmacist.

Administration

of Dexa-Polyspectran Drops to the eye.

The safety seal of the Thilo dropper bottle guarantees intact original filling and sterility of the product. The seal is broken with the first opening of the bottle.

Instil 1 drop into the conjunctival sac without touching the eye or the eyelid margin with the tip of the bottle.

Close the eyes for some seconds, then blink several times to distribute the drop evenly on the eye.





